Frontlight ResearchEarly access
Metastatic breast cancer trials in France
83 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in FranceEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Paris, Villejuif
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Besançon, Bordeaux, Brest, Bron, Caen Cedex 5, Lyon Cedex 04, Marseille, Montpellier Cedex 5, Paris, Pierre-Bénite, Rennes Cedex, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - Phase 3Not yet taking people in FranceA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Where
- Angers, Bayonne, Bobigny, Caen, Chambray-lès-Tours, Grenoble, Montpellier, Nancy, Nîmes, Paris, Pierre-Bénite, Valenciennes, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years to 130 years
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07647328 - Phase 1Taking peopleBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Where
- Bordeaux, Caen Cedex 5, Lille, Marseille, Paris, Rennes Cedex, St Herblain, Villejuif
- Age
- 18 years and over
- People
- 433 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00 - Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Caen, Lyon, Montpellier, Nantes, Paris, Poitiers
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - Phase 1/2Taking peopleTo compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
- Where
- Caen Cedex 5, Lille, Reims, Rennes Cedex, Villejuif
- Age
- 18 years and over
- People
- 73 worldwide
- Run by
- Genentech Inc.
See details and how to join2025-521128-31-00 - Phase 3Not yet taking people in FrancePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Amiens Cedex 1, Caen Cedex 5, Dijon, Le Mans, Marseille, Pierre-Bénite, Poitiers, Villejuif
- Age
- 18 years and over
- People
- 1,180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - Phase 4Taking peopleStudy Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
- Where
- Angers, Dijon, Lille, Marseille, Nîmes, Paris, Rennes, Strasbourg, Toulouse, Vandœuvre-lès-Nancy
- Age
- 18 years and over
- People
- 210
- Run by
- Institut Claudius Regaud
See details and how to joinNCT07195344 - Phase 1Taking peoplePhase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Where
- Paris, Saint-Herblain, Villejuif
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193 - Phase 3Taking peopleA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Where
- Clermont Ferrand Cedex 2, La Roche Sur Yon Cedex 9, Montpellier, Pierre-Bénite, Saint-Cloud
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00 - Phase 1Taking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Bordeaux, Lyon, Montpellier, Saint-Cloud, Saint-Herblain, Villejuif
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - Phase 1/2Not yet taking people in FranceA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Nîmes, Paris, Rennes, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - Phase 3Taking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Besancon Cedex, Bobigny, Brest, Bron, Limoges, Lyon Cedex 04, Marseille, Montpellier, Pierre-Bénite, Plérin, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - Phase 2Not yet taking people in FranceRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Dijon, Montpellier Cedex 5, Paris
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - Phase 1Taking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Lyon, Marseille, Toulouse, Vandoeuvre Les Nancy Cedex
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Lyon, Nîmes, Saint-Etienne
- Age
- 18 years and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - Phase 1/2Taking peopleDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Where
- Villejuif
- Age
- 18 years and over
- People
- 152
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT06298084 - Phase 1Not yet taking people in FranceA First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
- Where
- Villejuif
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Affibody AB
See details and how to join2024-518360-13-00 - Phase 2Taking peopleLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- Bordeaux, Clermont-Ferrand, Marseille, Montpellier Cedex 5, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Bordeaux, Saint-Herblain Cedex
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 3Not yet taking people in FranceElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Bordeaux, Dijon, Paris, Pierre-Bénite, Plérin, Saint-Priest-en-Jarez, Strasbourg, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseActive, not recruitingDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Amiens, Antony, Arras, Avignon, Bayonne, Besançon, Bordeaux, Bourg-en-Bresse, Caen, Chalon-sur-Saône, Chambéry, Chambray-lès-Tours, Cholet, Clermont-Ferrand, Compiègne, Créteil, Dechy, Dijon, Fort de France Cedex, Fréjus, Grenoble, La Chaussée-Saint-Victor, La Tronche, Le Mans, Le Puy-en-Velay, Levallois-Perret, Lille, Limoges, Lyon, Metz, Montivilliers, Montpellier, Neuilly-sur-Seine, Nice, Nîmes, Niort, Paris, Pau, Poitiers, Reims, Rennes, Rouen, Saint-Cloud, Saint-Paul, Sarcelles, Sens Cédex, Suresnes, Thionville, Toulon, Troyes, Valence, Valenciennes, Vandœuvre-lès-Nancy, Vannes, Villeurbanne
- Age
- 18 years and over
- People
- 2,295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - Phase 1/2Taking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Clermont Ferrand Cedex1, Dijon, La Tronche, Lyon, Marseille, Nantes, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - No phaseTaking peopleTherapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer
- Where
- Bourg-en-Bresse, Caluire-et-Cuire, Carcassonne, Contamine-sur-Arve, Le Puy-en-Velay, Mantes-la-Jolie, Montélimar, Saint-Priest-en-Jarez, Villeurbanne
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Centre Hospitalier Emile Roux
See details and how to joinNCT04794075 - Phase 2Taking peopleTesting Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
- Where
- Albi, Angers, Arras Cedex, Avignon, Beauvais, Bordeaux, Caen Cedex 5, Chambray-lès-Tours, Chauny, Clermont-Ferrand, Clermont Ferrand Cedex 2, Dechy, Dijon, Eaubonne, Epagny Metz-tessy, Frejus, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Osny, Paris, Poitiers, Reims, Saint-Cloud, Saint-Herblain Cedex, Saint-Priest-en-Jarez, St Nazaire, Strasbourg, Thonon-Les-Bains, Toulouse, Valence, Vandouvre Les Nancy, Villefranche Sur Saone Cedex, Villejuif
- Age
- 18 years and over
- People
- 260
- Run by
- UNICANCER
See details and how to joinNCT07151586 · EU 2025-521909-40-00